Measuring equitable delivery of vaccines

An elegant modelling study estimated that vaccination against ten infections, Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever, in 73 low and middle inco...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2020-03, Vol.38 (11), p.2433-2434
1. Verfasser: Durrheim, David N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2434
container_issue 11
container_start_page 2433
container_title Vaccine
container_volume 38
creator Durrheim, David N.
description An elegant modelling study estimated that vaccination against ten infections, Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever, in 73 low and middle income countries will have prevented an estimated 20 million deaths, 500 million cases of illness, 9 million cases of long-term disability and 960 million years of disability from 2001 to 2020 [1]. [...]it was commendable that the 2019 Lasker-Bloomberg Public Service Award was presented to Gavi, the Vaccine Alliance, for “providing sustained access to childhood vaccines around the globe, saving millions of lives, and highlighting the power of immunization to prevent disease”. By linking resourcing with increased equity of access, all vulnerable children, including those most difficult to reach, will be given higher prominence in recipient country health planning and service delivery. Measles can indeed be considered the “equity virus”: without vaccination, everyone gets measles, and without equitable health-care systems to deliver vaccination, measles will continue to present a threat to the most vulnerable [12]. [...]in a world where there is a coordinated global commitment to achieving Universal Health Coverage, measles incidence will be a sensitive marker of progress towards and achievement of this goal.
doi_str_mv 10.1016/j.vaccine.2020.01.099
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2353010254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X20301523</els_id><sourcerecordid>2353010254</sourcerecordid><originalsourceid>FETCH-LOGICAL-c341t-bc07a22827559ed8e91f27f88862fed442e3ae4b20396c2e56745087a7c6b4233</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRbP34CUrBi5fE2dmv5CQifoHiRcHbstlMZEua1N2m4L830urBi6e5PO_MOw9jJxxyDlxfzPO18z50lCMg5MBzKMsdNuWFERkqXuyyKaCWmeTwNmEHKc0BQAle7rOJQBDKgJmy8ydyaYihe5_RxxBWrmppVlMb1hQ_Z30z215JR2yvcW2i4-08ZK-3Ny_X99nj893D9dVj5oXkq6zyYBxigUapkuqCSt6gaYqi0NhQLSWScCSrsUCpPZLSRioojDNeVxKFOGTnm73L2H8MlFZ2EZKntnUd9UOyKJQADqjkiJ79Qef9ELuxnUWJSpfCaD1SakP52KcUqbHLGBYufloO9lulndvtk_ZbpQVuR5Vj7nS7fagWVP-mftyNwOUGoFHHOlC0yQfqPNUhkl_Zug__nPgCxt2EoA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425693766</pqid></control><display><type>article</type><title>Measuring equitable delivery of vaccines</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Durrheim, David N.</creator><creatorcontrib>Durrheim, David N.</creatorcontrib><description>An elegant modelling study estimated that vaccination against ten infections, Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever, in 73 low and middle income countries will have prevented an estimated 20 million deaths, 500 million cases of illness, 9 million cases of long-term disability and 960 million years of disability from 2001 to 2020 [1]. [...]it was commendable that the 2019 Lasker-Bloomberg Public Service Award was presented to Gavi, the Vaccine Alliance, for “providing sustained access to childhood vaccines around the globe, saving millions of lives, and highlighting the power of immunization to prevent disease”. By linking resourcing with increased equity of access, all vulnerable children, including those most difficult to reach, will be given higher prominence in recipient country health planning and service delivery. Measles can indeed be considered the “equity virus”: without vaccination, everyone gets measles, and without equitable health-care systems to deliver vaccination, measles will continue to present a threat to the most vulnerable [12]. [...]in a world where there is a coordinated global commitment to achieving Universal Health Coverage, measles incidence will be a sensitive marker of progress towards and achievement of this goal.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2020.01.099</identifier><identifier>PMID: 32035707</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Children ; Children &amp; youth ; Childrens health ; Diphtheria ; Drug delivery systems ; Encephalitis ; Equity ; Health care ; Health Equity ; Health planning ; Health services ; Hepatitis B ; Human papillomavirus ; Humans ; Immunization ; Immunization Programs - ethics ; Measles ; Public health ; Rotavirus ; Rubella ; Streptococcus infections ; Tetanus ; Vaccines ; Vaccines - administration &amp; dosage ; Vector-borne diseases ; Viruses ; Yellow fever</subject><ispartof>Vaccine, 2020-03, Vol.38 (11), p.2433-2434</ispartof><rights>2020 Elsevier Ltd</rights><rights>2020. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c341t-bc07a22827559ed8e91f27f88862fed442e3ae4b20396c2e56745087a7c6b4233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2425693766?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,64361,64363,64365,65309,72215</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32035707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Durrheim, David N.</creatorcontrib><title>Measuring equitable delivery of vaccines</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>An elegant modelling study estimated that vaccination against ten infections, Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever, in 73 low and middle income countries will have prevented an estimated 20 million deaths, 500 million cases of illness, 9 million cases of long-term disability and 960 million years of disability from 2001 to 2020 [1]. [...]it was commendable that the 2019 Lasker-Bloomberg Public Service Award was presented to Gavi, the Vaccine Alliance, for “providing sustained access to childhood vaccines around the globe, saving millions of lives, and highlighting the power of immunization to prevent disease”. By linking resourcing with increased equity of access, all vulnerable children, including those most difficult to reach, will be given higher prominence in recipient country health planning and service delivery. Measles can indeed be considered the “equity virus”: without vaccination, everyone gets measles, and without equitable health-care systems to deliver vaccination, measles will continue to present a threat to the most vulnerable [12]. [...]in a world where there is a coordinated global commitment to achieving Universal Health Coverage, measles incidence will be a sensitive marker of progress towards and achievement of this goal.</description><subject>Children</subject><subject>Children &amp; youth</subject><subject>Childrens health</subject><subject>Diphtheria</subject><subject>Drug delivery systems</subject><subject>Encephalitis</subject><subject>Equity</subject><subject>Health care</subject><subject>Health Equity</subject><subject>Health planning</subject><subject>Health services</subject><subject>Hepatitis B</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Programs - ethics</subject><subject>Measles</subject><subject>Public health</subject><subject>Rotavirus</subject><subject>Rubella</subject><subject>Streptococcus infections</subject><subject>Tetanus</subject><subject>Vaccines</subject><subject>Vaccines - administration &amp; dosage</subject><subject>Vector-borne diseases</subject><subject>Viruses</subject><subject>Yellow fever</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkE1Lw0AQhhdRbP34CUrBi5fE2dmv5CQifoHiRcHbstlMZEua1N2m4L830urBi6e5PO_MOw9jJxxyDlxfzPO18z50lCMg5MBzKMsdNuWFERkqXuyyKaCWmeTwNmEHKc0BQAle7rOJQBDKgJmy8ydyaYihe5_RxxBWrmppVlMb1hQ_Z30z215JR2yvcW2i4-08ZK-3Ny_X99nj893D9dVj5oXkq6zyYBxigUapkuqCSt6gaYqi0NhQLSWScCSrsUCpPZLSRioojDNeVxKFOGTnm73L2H8MlFZ2EZKntnUd9UOyKJQADqjkiJ79Qef9ELuxnUWJSpfCaD1SakP52KcUqbHLGBYufloO9lulndvtk_ZbpQVuR5Vj7nS7fagWVP-mftyNwOUGoFHHOlC0yQfqPNUhkl_Zug__nPgCxt2EoA</recordid><startdate>20200304</startdate><enddate>20200304</enddate><creator>Durrheim, David N.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20200304</creationdate><title>Measuring equitable delivery of vaccines</title><author>Durrheim, David N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c341t-bc07a22827559ed8e91f27f88862fed442e3ae4b20396c2e56745087a7c6b4233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Children</topic><topic>Children &amp; youth</topic><topic>Childrens health</topic><topic>Diphtheria</topic><topic>Drug delivery systems</topic><topic>Encephalitis</topic><topic>Equity</topic><topic>Health care</topic><topic>Health Equity</topic><topic>Health planning</topic><topic>Health services</topic><topic>Hepatitis B</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Programs - ethics</topic><topic>Measles</topic><topic>Public health</topic><topic>Rotavirus</topic><topic>Rubella</topic><topic>Streptococcus infections</topic><topic>Tetanus</topic><topic>Vaccines</topic><topic>Vaccines - administration &amp; dosage</topic><topic>Vector-borne diseases</topic><topic>Viruses</topic><topic>Yellow fever</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Durrheim, David N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Durrheim, David N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Measuring equitable delivery of vaccines</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2020-03-04</date><risdate>2020</risdate><volume>38</volume><issue>11</issue><spage>2433</spage><epage>2434</epage><pages>2433-2434</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>An elegant modelling study estimated that vaccination against ten infections, Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever, in 73 low and middle income countries will have prevented an estimated 20 million deaths, 500 million cases of illness, 9 million cases of long-term disability and 960 million years of disability from 2001 to 2020 [1]. [...]it was commendable that the 2019 Lasker-Bloomberg Public Service Award was presented to Gavi, the Vaccine Alliance, for “providing sustained access to childhood vaccines around the globe, saving millions of lives, and highlighting the power of immunization to prevent disease”. By linking resourcing with increased equity of access, all vulnerable children, including those most difficult to reach, will be given higher prominence in recipient country health planning and service delivery. Measles can indeed be considered the “equity virus”: without vaccination, everyone gets measles, and without equitable health-care systems to deliver vaccination, measles will continue to present a threat to the most vulnerable [12]. [...]in a world where there is a coordinated global commitment to achieving Universal Health Coverage, measles incidence will be a sensitive marker of progress towards and achievement of this goal.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>32035707</pmid><doi>10.1016/j.vaccine.2020.01.099</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2020-03, Vol.38 (11), p.2433-2434
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_2353010254
source MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland
subjects Children
Children & youth
Childrens health
Diphtheria
Drug delivery systems
Encephalitis
Equity
Health care
Health Equity
Health planning
Health services
Hepatitis B
Human papillomavirus
Humans
Immunization
Immunization Programs - ethics
Measles
Public health
Rotavirus
Rubella
Streptococcus infections
Tetanus
Vaccines
Vaccines - administration & dosage
Vector-borne diseases
Viruses
Yellow fever
title Measuring equitable delivery of vaccines
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T13%3A47%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Measuring%20equitable%20delivery%20of%20vaccines&rft.jtitle=Vaccine&rft.au=Durrheim,%20David%20N.&rft.date=2020-03-04&rft.volume=38&rft.issue=11&rft.spage=2433&rft.epage=2434&rft.pages=2433-2434&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2020.01.099&rft_dat=%3Cproquest_cross%3E2353010254%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425693766&rft_id=info:pmid/32035707&rft_els_id=S0264410X20301523&rfr_iscdi=true